Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Computed tomographic angiography with three‐dimensional reconstruction for transoral laser microsurgery
Salassa, John R., Özgürsoy, Ozan Bağış , Weindling, Steven M. , Casler, John D.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | February 19, 2010 | Volume: 142 | Issue: 3 | Pages: 351-354

10.1016/j.otohns.2009.11.028 | PMID 20172379 Get It

ObjectiveTo identify major arteries in relationship to large pharyngeal tumors during transoral laser microsurgery.Study DesignCase series with planned data collection.SettingMayo Clinic, Jacksonville, Florida.Subjects and MethodsWe developed a new technique that combines three‐dimensional CT angiography and enhanced soft‐tissue neck CT for evaluation of pharyngeal tumors before transoral laser microsurgery. Data from CT angiography were used to create three‐dimensional images of the tumor and adjacent arterial branches to better orient the surgeon to the spatial relationships of major arteries and pharyngeal tumors. Included were selected patients who had large tumors involving the pharynx and who underwent transoral laser microsurgery.ResultsEighteen patients were studied from June 2008 through January 2009. Tumor enhancement was absent or modest in four of 18 patients. Three of these four patients had superficial squamous cell carcinomas and one had adenoid cystic carcinoma. The remaining 14 patients had good tumor enhancement. The tumor involved the lingual artery in three and displaced the lingual or facial artery in two of these 14 patients. One anomalous right inferior thyroid artery was identified. Compared with routine enhanced soft‐tissue neck CT, three‐dimensional CT angiography greatly enhanced the anatomical relationships of the major arteries. In one patient, the surgeon's approach was changed after three‐dimensional CT angiography demonstrated an encased lingual artery.ConclusionThree‐dimensional CT angiography was useful in identifying the anatomical orientation of major arteries and the planning of transoral laser microsurgery to treat tumors involving the pharynx.
Trends in Incidence, Severity, and Outcome of Hospitalized Myocardial Infarction
Roger, Véronique L. , Weston, Susan A., Gerber, Yariv , Killian, Jill M. , Jaffe, Allan S. , Bell, Malcolm R. , Kors, Jan A. , Yawn, Barbara P. , Jacobsen, Steven J. , Dunlay, Shannon M. , Jaffe, Allan S.

Mayo Clinic

Circulation | February 9, 2010 | Volume: 121 | Issue: 7 | Pages: 863-869

10.1161/circulationaha.109.897249 | PMID 20142444 Get It

Background— In 2000, the definition of myocardial infarction (MI) changed to rely on troponin rather than creatine kinase (CK) and its MB fraction (CK-MB). The implications of this change on trends in MI incidence and outcome are not defined. Methods and Results— This was a community study of 2816 patients hospitalized with incident MI from 1987 to 2006 in Olmsted County, Minnesota, with prospective measurements of troponin and CK-MB from August 2000 forward. Outcomes were MI incidence, severity, and survival. After troponin was introduced, 278 (25%) of 1127 incident MIs met only troponin-based criteria. When cases meeting only troponin criteria were included, incidence did not change between 1987 and 2006. When restricted to cases defined by CK/CK-MB, the incidence of MI declined by 20%. The incidence of non–ST-segment elevation MI increased markedly by relying on troponin, whereas that of ST-segment elevation MI declined regardless of troponin. The age- and sex-adjusted hazard ratio of death within 30 days for an infarction occurring in 2006 (compared with 1987) was 0.44 (95% confidence interval, 0.30 to 0.64). Among 30-day survivors, survival did not improve, but causes of death shifted from cardiovascular to noncardiovascular ( P =0.001). Trends in long-term survival among 30-day survivors were similar regardless of troponin. Conclusions— Over the last 2 decades, a substantial change in the epidemiology of MI occurred that was only partially mediated by the introduction of troponin. Non–ST-segment elevation MIs now constitute the majority of MIs. Although the 30-day case fatality improved markedly, long-term survival did not change, and the cause of death shifted from cardiovascular to noncardiovascular.
Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-6
Mahoney, Michelle R., Nagorney, David M. , Wagman, Lawrence D., Smyrk, Thomas C. , Weiland, Timothy L., Lai, Lily , Schwarz, Roderich E. , Molina, R, Dentchev, Todor, Bolton, John S. , Alberts, Steven R. , Roh, Mark S. , O’Connell, Michael J.

Mayo Clinic

Journal of Clinical Oncology | January 5, 2010 | Volume: 28 | Issue: 5 | Pages: 853-858

10.1200/jco.2009.24.6728 | PMID 20048179 Get It

Purpose Prior trials have shown that surgery followed by hepatic artery infusion (HAI) of floxuridine (FUDR) alternating with systemic fluorouracil improves survival rates. Oxaliplatin combined with capecitabine has demonstrated activity in advanced colorectal cancer. Based on this observation a trial was conducted to assess the potential benefit of systemic oxaliplatin and capecitabine alternating with HAI of FUDR. The primary end point was 2-year survival. Patients and Methods Patients with liver-only metastases from colorectal cancer amenable to resection or cryoablation were eligible. HAI and systemic therapy was initiated after metastasectomy. Alternating courses of HAI consisted of 0.2 mg/m2/d FUDR and dexamethasone, day 1 through 14 weeks 1 and 2. Systemic therapy included oxaliplatin 130 mg/m2 day 1 with capecitabine at 1,000 mg/m2 twice daily, days 1 through 14, weeks 4 and 5. Two additional 3-week courses of systemic therapy were given. Capecitabine was reduced to 850 mg/m2 twice daily after interim review of toxicity. Results Fifty-five of 76 eligible patients were able to initiate protocol-directed therapy and completed median of six cycles (range, one to six). Three postoperative or treatment-related deaths were reported. Overall, 88% of evaluable patients were alive at 2 years. With a median follow-up of 4.8 years, a total of 30 patients have had disease recurrence, 11 involving the liver. Median disease-free survival was 32.7 months. Conclusion Alternating HAI of FUDR and systemic capecitabine and oxaliplatin met the prespecified end point of higher than 85% survival at 2 years and was clinically tolerable. However, the merits of this approach need to be established with a phase III trial.
Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set
Gramont, Aimery de , Shi, Qian , Benedetti, Jacqueline, Bot, Brian M. , O’Callaghan, Chris J. , Yothers, Greg , Goldberg, Richard M. , Blanke, Charles D. , Benson, Al B. , Deng, Qiqi , André, Thierry , Sargent, Daniel J. , Hubbard, Joleen M. , O’Connell, Michael J. , Buyse, Marc , Alberts, Steven R. , Wolmark, Norman , Grothey, Axel , Sargent, Daniel J , André, Thierry , Shi, Qian , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | December 15, 2009 | Volume: 28 | Issue: 3 | Pages: 460-465

10.1200/jco.2009.23.1407 | PMID 20008641 Get It

Purpose We previously validated disease-free survival (DFS) as a surrogate for overall survival (OS) in fluorouracil-based adjuvant colon cancer clinical trials. New therapies have extended survival after recurrence from 1 to approximately 2 years. We examined the possible impact of this improvement on the DFS/OS association. Methods The Adjuvant Colon Cancer Endpoints (ACCENT) data set of 20,898 patients was analyzed. In an exploratory fashion, time from recurrence to death in patients experiencing recurrence was extended using several algorithms, and the association of DFS after 3 years of median follow-up and OS after varying lengths of follow-up (median of 5, 6, and 7 years) was assessed. Results Seven thousand four hundred two patients (35%) experienced recurrence. Median time from recurrence to death was 24 months in the hypothetical data sets. When times from recurrence to death were doubled, the association between treatment effects on DFS and 5-year OS was modest (R2 = 0.51 for both 2- and 3-year DFS) but remained strong for DFS and 6-year OS (R2 = 0.67 for both 2- and 3-year DFS) and 7-year OS (R2 = 0.70 for both 2- and 3-year DFS). The reduced DFS/OS association with extended survival after recurrence was greater in stage II than stage III patients. Multiple simulations provided consistent findings. Conclusion Extended survival after recurrence reduces the association between treatment effects on 3-year DFS and 5-year OS, particularly in stage II patients; longer follow-up strengthens the association. In modern adjuvant trials, 6 or 7 years may be required to demonstrate OS improvements, further supporting DFS as the preferred primary end point for future adjuvant colon cancer clinical trials.
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
Gay, Francesca , Hayman, Suzanne R. , Lacy, Martha Q. , Kumar, Shaji , Dispenzieri, Angela , Bergsagel, P. Leif , Dingli, David , Reeder, Craig B. , Lust, John A., Russell, Stephen J. , Zeldenrust, Steven R., Fonseca, Rafaël , Kyle, Robert A. , Greipp, Philip R., Stewart, A. Keith, Rajkumar, S. Vincent , Buadi, Francis K. , Gertz, Morie A. , Mıkhael, Joseph , Roy, Vivek , Witzig, Thomas E. , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Gay, Francesca , Fonseca, Rafael

Mayo Clinic

Blood | December 12, 2009 | Volume: 115 | Issue: 7 | Pages: 1343-1350

10.1182/blood-2009-08-239046 | PMID 20008302 Get It

AbstractThe objective of this case-control study was to compare the efficacy and toxicity of lenalidomide plus dexamethasone (len/dex) versus thalidomide plus dexamethasone (thal/dex) as initial therapy for newly diagnosed myeloma. We retrospectively studied 411 newly diagnosed patients treated with len/dex (228) or thal/dex (183) at the Mayo Clinic. The differences were similar in a matched-pair analysis that adjusted for age, sex, transplantation status, and dexamethasone dose. The proportions of patients achieving at least a partial response to len/dex and thal/dex were 80.3% versus 61.2%, respectively (P < .001); very good partial response rates were 34.2% and 12.0%, respectively (P < .001). Patients receiving len/dex had longer time to progression (median, 27.4 vs 17.2 months; P = .019), progression-free survival (median, 26.7 vs 17.1 months; P = .036), and overall survival (median not reached vs 57.2 months; P = .018). A similar proportion of patients in the 2 groups experienced at least one grade 3 or 4 adverse event (57.5% vs 54.6%, P = .568). Main grade 3 or 4 toxicities of len/dex were hematologic, mainly neutropenia (14.6% vs 0.6%, P < .001); the most common toxicities in thal/dex were venous thromboembolism (15.3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results.
Paravertebral Block Provides Significant Opioid Sparing After Hand-Assisted Laparoscopic Nephrectomy: An Expanded Case Report of 30 Patients
Clendenen, Steven R. , Wehle, Michael J., Rodriguez, Gabriel A., Greengrass, Roy A.

Mayo Clinic

Journal of Endourology | November 17, 2009 | Volume: 23 | Issue: 12 | Pages: 1979-1983

10.1089/end.2009.0095 | PMID 19919257 Get It

Molecular mechanisms of Cryptosporidium -induced host actin cytoskeleton dynamics.
O’Hara, Steven P. , Chen, X. M., LaRusso, N. F., Chen, X. M.

Mayo Clinic

Giardia and Cryptosporidium: from molecules to disease | November 16, 2009 | Volume: No volume available | Issue: No issue available | Pages: 418-427

10.1079/9781845933913.0418 Get It

Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426
Adjei, Alex A. , Mandrekar, Sumithra J. , Dy, Grace K. , Molina, Julian R. , Adjei, Araba A., Gandara, David R. , Ziegler, Katie L. Allen, Stella, Philip J., Rowland, Kendrith M. , Schild, Steven E. , Zinner, Ralph , Schild, Steven , Gandara, David

Mayo Clinic

Journal of Clinical Oncology | October 20, 2009 | Volume: 28 | Issue: 4 | Pages: 614-619

10.1200/jco.2009.23.6406 | PMID 19841321 Get It

Purpose To evaluate the efficacy and toxicity of pemetrexed combined with bevacizumab as second-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) and to correlate allelic variants in pemetrexed-metabolizing genes with clinical outcome. Patients and Methods Patients with previously treated NSCLC received pemetrexed (500 mg/m2 intravenous) combined with bevacizumab (15 mg/kg intravenous) every 3 weeks. The primary end point, evaluated using a one-stage Fleming design for detecting a true success rate of at least 70%, was the proportion of patients who were progression free and on treatment at 3 months. Polymorphisms in genes responsible for pemetrexed transport (reduced folate carrier [SLC19A1]) and metabolism (folylpolyglutamate synthase [FPGS] and gamma-glutamyl hydrolase [GGH]) evaluated in germline DNA (blood) were correlated with treatment outcome. Results Forty-eight evaluable patients (14 females and 34 males) received a median of four cycles (range, one to 20 cycles). The most common grade 3 or 4 nonhematologic adverse events (AEs) were fatigue (13%), dyspnea (10%), and thrombosis (10%). Grade 3 or 4 hematologic AEs were neutropenia (19%) and lymphopenia (13%). Twenty-four (57%; 95% CI, 41% to 72%) of the first 42 patients met the success criteria. Median overall survival (OS) and progression-free survival (PFS) times were 8.6 and 4.0 months, respectively. The exon 6 (2522)C→T polymorphism in SLC19A1 correlated with 3-month progression-free status (P = .01) and with PFS (P = .05). The IVS1(1307)C→T polymorphism in GGH correlated with OS (P = .04). Conclusion The study did not meet its primary end point. However, the median PFS time of 4 months is promising. Pharmacogenetic studies in larger cohorts are needed to definitively identify polymorphisms that predict for survival and toxicity of pemetrexed.
Intravesical Prostatic Protrusion in Men in Olmsted County, Minnesota
Lieber, Michael M., Jacobson, Debra J., McGree, Michaela E. , Sauver, Jennifer L. St. , Jacobsen, Steven J. , Girman, Cynthia J. , St Sauver, Jennifer L

Mayo Clinic

Journal of Urology | October 18, 2009 | Volume: 182 | Issue: 6 | Pages: 2819-2824

10.1016/j.juro.2009.08.086 | PMID 19837429 Get It